Radioiodine (RAI) is selectively recommended for intermediate-risk differentiated thyroid
carcinomas (DTC). The information gleaned from pretherapy stimulated thyroglobulin levels …

Background: Diagnostic radioiodine whole-body scanning (DxWBS) in combination with
stimulated thyroglobulin (Tg)(ie, measurement after levothyroxine [L-T4] withdrawal or …

Background A diagnostic I-131 (Dx) scan is used to detect a thyroid remnant or metastases
before treatment of differentiated thyroid cancer (DTC) with I-131. The aim of this study is to …

Background: Recently, there has been a trend to reduce the use of radioiodine remnant
ablation (RRA) in patients with low-risk (LR) and intermediate-risk (IR) differentiated thyroid …

Background Differentiated thyroid cancer (DTC) work-up is based on (near) total-
thyroidectomy plus thyroid remnant ablation (TRA) with 131-radioiodine in many patients …

Context: The use of preablation diagnostic radioiodine scans for risk stratification and
radioiodine therapy planning for differentiated thyroid cancer (DTC) remains controversial …

Abstract Purpose Around 10–27% of patients will present elevated thyroglobulin (Tg) levels
and negative diagnostic whole-body scan (dxWBS) during differentiated thyroid cancer …

Simple Summary In patients with differentiated thyroid cancer, the standard treatment
consists in surgery followed by radioactive iodine (RAI) therapy. Follow-up is usually …

Background: A diagnostic whole-body scan (WBS) is recommended 6 to 12 months after
total thyroidectomy and radioactive iodide ablation in intermediate-or high-risk patients with …

Purpose Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have
rarely been analyzed. The purpose of the present study was to find clinical and pathological …